Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the appointment of Robert Bitterman as interim Executive Chairman of the Board, taking on roles of principal executive officer and principal financial officer. Bitterman, with 25 years in the pharmaceutical sector, has been a board director since 2012. The company also appointed Robert Ferrara as Lead Independent Director, who has board experience since 2019 and extensive financial expertise. These leadership changes aim to enhance operational oversight and strategic direction.
- Robert Bitterman brings 25 years of executive leadership experience in pharmaceuticals.
- Leadership changes may strengthen operational oversight and strategic direction.
- The interim nature of the Executive Chairman position may raise continuity concerns.
MARLBOROUGH, Mass., Sept. 29, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors (the "Board"). As Executive Chairman, Mr. Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company's operations. Mr. Bitterman has served as a director on the Company's Board since 2012 and brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry coupled with prior experience in senior financial and investor relations roles.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
The Company is also pleased to announce the appointment of Robert Ferrara as Lead Independent Director of the Board. Mr. Ferrara currently serves as the Chairman of the Audit Committee of the Board. With his appointment, Mr. Ferrara will assume the duties and responsibilities of Lead Independent Director. Mr. Ferrara has served as a director on the Company's Board since 2019 and has held numerous senior executive level financial positions in both domestic and international public and private companies in a variety of industries, including pharmaceuticals and life sciences. Mr. Ferrara is a Certified Public Accountant and earned a BS degree in accounting from Lehigh University.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company's goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman-301636146.html
SOURCE Phio Pharmaceuticals Corp.
FAQ
Who is the new Executive Chairman of Phio Pharmaceuticals?
What are the responsibilities of Robert Bitterman at Phio Pharmaceuticals?
When was Robert Bitterman appointed as Executive Chairman?
Who is the Lead Independent Director at Phio Pharmaceuticals?
What is the experience of Robert Ferrara at Phio Pharmaceuticals?
